文献速递慢性肾脏病

常规测量的碘海醇肾小球滤过率与基于肌酐的估算肾小球滤过率对晚期慢性肾脏病患者死亡的预测比较:一项瑞典慢性肾脏病登记队列研究

Routinely measured iohexol glomerular filtration rate versus creatinine-based estimated glomerular filtration rate as predictors of mortality in patients with advanced chronic kidney disease: a Swedish Chronic Kidney Disease Registry cohort study.
PubMed 文献 · Nephrol Dial Transplant · 2017-01-01

该研究利用瑞典慢性肾脏病登记(2005-11)链接全国住院、透析和死亡登记,在2705例CKD 4/5期成人中比较血浆碘海醇实测GFR(mGFR)与基于肌酐的估算GFR(eGFR)预测死亡的表现。中位随访45个月,记录968例死亡(36%)。完全校正Cox模型中,mGFR每升高1 mL/min/1.73 m²与全因死亡风险降低5.3%相关,eGFR相应降低1.7%[aHR 0.947(95%CI 0.930-0.964)vs aHR 0.983(95%CI 0.970-0.996)];mGFR在预后模型中统计学更优。

要点

  • 在CKD 4/5期成人中,mGFR每升高1 mL/min/1.73 m²与全因死亡风险降低5.3%相关,eGFR相应降低1.7%。
  • mGFR在病因学和预后模型中预测死亡的表现均统计学优于eGFR。
  • mGFR的改善幅度相对有限,提示eGFR可能足以用于日常临床实践,而mGFR可为认为eGFR有偏倚者增加重要预后信息。

核心结论

  • 在CKD 4/5期成人中,mGFR在病因学和预后模型中预测死亡的表现均优于eGFR,说明GFR本身相对于非GFR结局决定因素的重要性。
  • mGFR的改善相对有限,提示eGFR可能足以用于日常临床实践,而mGFR可为认为eGFR有偏倚者增加重要预后信息。

研究设计与样本

  • 利用瑞典慢性肾脏病登记(2005-11),链接全国住院、透析和死亡登记。
  • 在CKD 4/5期成人中比较血浆碘海醇实测GFR(mGFR)和尿液清除率测量与eGFR预测死亡的表现。
  • 共2705例患者,其中1517例进行了mGFR,其余提供24小时尿液清除率。
  • 采用生存和预后模型评估表现。

主要发现

  • 中位eGFR(CKD-EPI肌酐)为20 mL/min/1.73 m²(IQR 14-26),mGFR为18 mL/min/1.73 m²(IQR 13-23),肌酐清除率为23 mL/min(IQR 15-31)。
  • 中位随访45个月(IQR 26-59),记录968例死亡(36%)。
  • 完全校正Cox模型中,mGFR每升高1 mL/min/1.73 m²与全因死亡风险降低5.3%相关,eGFR相应降低1.7%[aHR 0.947(95%CI 0.930-0.964)vs aHR 0.983(95%CI 0.970-0.996)]。
  • mGFR在预后模型中统计学更优(采用逻辑回归的判别和集成判别改善)。
  • 尿液清除率测量与死亡的病因学关系强于eGFR,但在预后模型中未统计学更优。

关键数值与推荐

  • 中位eGFR(CKD-EPI肌酐)20 mL/min/1.73 m²(IQR 14-26),mGFR 18 mL/min/1.73 m²(IQR 13-23),肌酐清除率23 mL/min(IQR 15-31)。
  • mGFR每升高1 mL/min/1.73 m²与全因死亡风险降低5.3%相关,eGFR相应降低1.7%[aHR 0.947(95%CI 0.930-0.964)vs aHR 0.983(95%CI 0.970-0.996)]。

临床怎么用

  • mGFR的改善相对有限,提示eGFR可能足以用于日常临床实践,而mGFR可为认为eGFR有偏倚者增加重要预后信息。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Estimated glomerular filtration rate (eGFR) becomes less reliable in patients with advanced chronic kidney disease (CKD). METHODS: Using the Swedish CKD Registry (2005-11), linked to the national inpatient, dialysis and death registers, we compared the performance of plasma-iohexol measured GFR (mGFR) and urinary clearance measures versus eGFR to predict death in adults with CKD stages 4/5. Performance was assessed using survival and prognostic models. RESULTS: Of the 2705 patients, 1517 had mGFR performed, with the remainder providing 24-h urine clearances. Median eGFR (CKD-EPI creatinine ) was 20 mL/min/1.73 m 2 [interquartile range (IQR) 14-26], mGFR 18 mL/min/1.73 m 2 (IQR 13-23) and creatinine clearance 23 mL/min (IQR 15-31). Median follow-up was 45 months (IQR 26-59), registering 968 deaths (36%). In fully adjusted Cox models, a rise in mGFR of 1 mL/min/1.73 m 2 was associated with a 5.3% fall in all-cause mortality compared with a 1.7% corresponding fall for eGFR [adjusted hazard ratio (aHR) 0.947 (95% CI, 0.930-0.964) versus aHR 0.983 (95% CI, 0.970-0.996)]. mGFR was also statistically superior in prognostic models (discrimination using logistic regression and integrated discrimination improvement). Urinary clearance measures showed a stronger aetiological relationship with death than eGFR, but were not statistically superior in the prognostic models. CONCLUSIONS: The performance of mGFR was superior to eGFR, in both aetiological and prognostic models, in predicting mortality in adults with CKD stage 4/5, demonstrating the importance of GFR per se versus non-GFR determinants of outcome. However, the relatively modest enhancement suggests that eGFR may be sufficient to use in everyday clinical practice while mGFR adds important prognostic information for those where eGFR is believed to be biased.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Methven S, Gasparini A, Carrero JJ, et al. Routinely measured iohexol glomerular filtration rate versus creatinine-based estimated glomerular filtration rate as predictors of mortality in patients with advanced chronic kidney disease: a Swedish Chronic Kidney Disease Registry cohort study. Nephrol Dial Transplant. 2017. PMID: 28339801. doi:10.1093/ndt/gfw457

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。